{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T22:29:29Z","timestamp":1793917769631,"version":"4.8.0"},"reference-count":50,"publisher":"American Society of Hematology","issue":"15","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2011,10,13]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Chronic GVHD is one of the most severe complications of allogeneic HSCT. The sclerotic skin manifestations of cGVHD (ScGVHD) result from inflammation and fibrosis of the dermis, subcutaneous tissue, or fascia, leading to significant functional disability. Risk factors and clinical markers associated with ScGVHD remain largely unexamined. By using a single-visit, cross-sectional design, we evaluated 206 patients with cGVHD at the National Institutes of Health. Most patients manifested severe (ie, 63% National Institutes of Health score \u201csevere\u201d), refractory disease (median treatments = 4). ScGVHD was detected in 109 (52.9%) patients. ScGVHD was associated with greater platelet count (P &lt; .001) and C3 (P &lt; .001), and decreased forced vital capacity (P = .013). Total body irradiation (TBI) was associated with development of ScGVHD (P = .002). TBI administered in reduced-intensity conditioning was most strongly associated with ScGVHD (14\/15 patients, P &lt; .0001). Patients with ScGVHD had significant impairments of joint range of motion and grip strength (P &lt; .001). Greater body surface area involvement was associated with poorer survival (P = .015). We conclude that TBI, particularly in reduced-intensity regimens, may be an important risk factor for ScGVHD. Widespread skin involvement is associated with significant functional impairment, distressing symptoms, and diminished survival. This trial is registered at http:\/\/www.clinicaltrials.gov as NCT00331968.<\/jats:p>","DOI":"10.1182\/blood-2011-04-350249","type":"journal-article","created":{"date-parts":[[2011,7,26]],"date-time":"2011-07-26T20:13:27Z","timestamp":1311711207000},"page":"4250-4257","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":118,"title":["Sclerotic-type chronic GVHD of the skin: clinical risk factors, laboratory markers, and burden of disease"],"prefix":"10.1182","volume":"118","author":[{"given":"Kathryn J.","family":"Martires","sequence":"first","affiliation":[{"name":"Dermatology Branch,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristin","family":"Baird","sequence":"additional","affiliation":[{"name":"Pediatric Oncology Branch,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seth M.","family":"Steinberg","sequence":"additional","affiliation":[{"name":"Biostatistics and Data Management Section, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lana","family":"Grkovic","sequence":"additional","affiliation":[{"name":"Experimental Transplantation and Immunology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Galen O.","family":"Joe","sequence":"additional","affiliation":[{"name":"Department of Rehabilitation Medicine, National Institutes of Health Clinical Center, Bethesda, MD;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirsten M.","family":"Williams","sequence":"additional","affiliation":[{"name":"Experimental Transplantation and Immunology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra A.","family":"Mitchell","sequence":"additional","affiliation":[{"name":"Outcomes Research Branch, Division of Cancer Control and Population Sciences, National Cancer Institute, Bethesda, MD; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Datiles","sequence":"additional","affiliation":[{"name":"National Eye Institute, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran T.","family":"Hakim","sequence":"additional","affiliation":[{"name":"Experimental Transplantation and Immunology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven Z.","family":"Pavletic","sequence":"additional","affiliation":[{"name":"Experimental Transplantation and Immunology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward W.","family":"Cowen","sequence":"additional","affiliation":[{"name":"Dermatology Branch,"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"2","key":"2019111807103569200_B1","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1182\/blood-2002-01-0011","article-title":"Comparison of chronic graft-versus-host disease after transplantation of peripheral blood stem cells versus bone marrow in allogeneic recipients: long-term follow-up of a randomized trial.","volume":"100","author":"Flowers","year":"2002","journal-title":"Blood"},{"issue":"7","key":"2019111807103569200_B2","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1001\/archderm.138.7.924","article-title":"Sclerodermatous graft-vs-host disease: clinical and pathological study of 17 patients.","volume":"138","author":"Pe\u00f1as","year":"2002","journal-title":"Arch Dermatol"},{"issue":"1","key":"2019111807103569200_B3","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/0190-9622(92)70005-Z","article-title":"Sclerodermatous chronic graft-versus-host disease. Analysis of seven cases.","volume":"26","author":"Chosidow","year":"1992","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"2019111807103569200_B4","first-page":"258","article-title":"Sclerodermatous chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation: incidence, predictors and outcome.","volume":"91","author":"Skert","year":"2006","journal-title":"Haematologica"},{"key":"2019111807103569200_B5","volume-title":"Clinical Bone Marrow and Blood Stem Cell Transplantation","author":"Atkinson","year":"2004","edition":"3rd ed"},{"issue":"4","key":"2019111807103569200_B6","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.bbmt.2006.02.003","article-title":"Ancillary therapy and supportive care of chronic graft-versus-host disease: national institutes of health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: V. Ancillary Therapy and Supportive Care Working Group Report.","volume":"12","author":"Couriel","year":"2006","journal-title":"Biol Blood Marrow Transplant"},{"issue":"5","key":"2019111807103569200_B7","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.bbmt.2010.07.025","article-title":"Therapy of sclerodermatous chronic graft-versus-host disease with mammalian target of rapamycin inhibitors.","volume":"17","author":"Jedlickova","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"issue":"12","key":"2019111807103569200_B8","doi-asserted-by":"crossref","first-page":"993","DOI":"10.7326\/0003-4819-120-12-199406150-00004","article-title":"Fasciitis in chronic graft-versus-host disease. A clinicopathologic study of 14 cases.","volume":"120","author":"Janin","year":"1994","journal-title":"Ann Intern Med"},{"issue":"5","key":"2019111807103569200_B9","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1111\/j.1365-2133.1996.tb06314.x","article-title":"Specificity of antinuclear antibodies in scleroderma-like chronic graft-versus-host disease: clinical correlation and histocompatibility locus antigen association.","volume":"134","author":"Bell","year":"1996","journal-title":"Br J Dermatol"},{"issue":"1","key":"2019111807103569200_B10","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1177\/039463201002300139","article-title":"Clinical, serologic and instrumental data of ten patients affected by sclerodermatous chronic graft versus host disease: similarities and differences in respect to systemic sclerosis.","volume":"23","author":"Barausse","year":"2010","journal-title":"Int J Immunopathol Pharmacol"},{"issue":"4","key":"2019111807103569200_B11","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.jaad.2005.06.015","article-title":"Lichen sclerosus and eosinophilic fasciitis as manifestations of chronic graft-versus-host disease: expanding the sclerodermoid spectrum.","volume":"53","author":"Schaffer","year":"2005","journal-title":"J Am Acad Dermatol"},{"issue":"12","key":"2019111807103569200_B12","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/j.bbmt.2005.09.004","article-title":"National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report.","volume":"11","author":"Filipovich","year":"2005","journal-title":"Biol Blood Marrow Transplant"},{"issue":"8","key":"2019111807103569200_B13","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1053\/bbmt.2002.v8.pm12234170","article-title":"Development and validation of a scale to measure symptoms of chronic graft-versus-host disease.","volume":"8","author":"Lee","year":"2002","journal-title":"Biol Blood Marrow Transplant"},{"key":"2019111807103569200_B14","volume-title":"American Academy of Orthopaedic Surgeons. Joint Motion: Method of Measuring and Recording","author":"Burrows","year":"1965"},{"issue":"382","key":"2019111807103569200_B15","first-page":"427","article-title":"A network algorithm for performing Fisher's exact test in r \u00d7 c contingency tables.","volume":"78","author":"Mehta","year":"1983","journal-title":"J Am Stat Assoc"},{"key":"2019111807103569200_B16","doi-asserted-by":"crossref","DOI":"10.1002\/0471249688","volume-title":"Categorical Data Analysis","author":"Agresti","year":"2002","edition":"2nd ed"},{"key":"2019111807103569200_B17","volume-title":"Nonparametric Statistical Methods","author":"Hollander","year":"1999","edition":"2nd ed"},{"issue":"11","key":"2019111807103569200_B18","doi-asserted-by":"crossref","first-page":"3214","DOI":"10.1182\/blood-2010-08-302109","article-title":"Comparative analysis of risk factors for acute and for chronic graft-versus-host-disease according to National Institute of Health consensus criteria.","volume":"117","author":"Flowers","year":"2011","journal-title":"Blood"},{"issue":"35","key":"2019111807103569200_B19","doi-asserted-by":"crossref","first-page":"5728","DOI":"10.1200\/JCO.2008.17.6545","article-title":"Risk factors for acute graft-versus-host disease after human leukocyte antigen-identical sibling transplants for adults with leukemia.","volume":"26","author":"Hahn","year":"2008","journal-title":"J. Clin. Oncol"},{"issue":"6","key":"2019111807103569200_B20","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/sj.bmt.1705597","article-title":"High-dose chemotherapy using BEAM without autologous rescue followed by reduced-intensity conditioning allogeneic stem-cell transplantation for refractory or relapsing lymphomas: a comparison of delayed versus immediate transplantation.","volume":"39","author":"Buser","year":"2007","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"2019111807103569200_B21","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1182\/blood-2002-08-2628","article-title":"Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation.","volume":"102","author":"Mielcarek","year":"2003","journal-title":"Blood"},{"issue":"2","key":"2019111807103569200_B22","doi-asserted-by":"crossref","first-page":"E187","DOI":"10.1111\/j.1399-0012.2010.01361.x","article-title":"Comparison of reduced intensity and myeloablative conditioning regimens for stem cell transplantation in patients with malignancies: a meta-analysis.","volume":"25","author":"Shi-Xia","year":"2011","journal-title":"Clin Transplant"},{"issue":"5426","key":"2019111807103569200_B23","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1126\/science.285.5426.412","article-title":"Prevention of graft versus host disease by inactivation of host antigen-presenting cells.","volume":"285","author":"Shlomchik","year":"1999","journal-title":"Science"},{"issue":"8177","key":"2019111807103569200_B24","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/S0140-6736(80)91519-6","article-title":"Graft-versus-host disease limited to area of irradiated skin.","volume":"1","author":"Zwaan","year":"1980","journal-title":"Lancet"},{"issue":"1","key":"2019111807103569200_B25","first-page":"133","article-title":"Unusual localization of cutaneous chronic graft-versus-host disease in the radiation fields in four cases.","volume":"4","author":"Socie","year":"1989","journal-title":"Bone Marrow Transplant"},{"issue":"9","key":"2019111807103569200_B26","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1001\/archdermatol.2011.226","article-title":"Localization of sclerotic-type chronic graft-versus-host disease to sites of skin injury: potential insight into the mechanism of isomorphic and isotopic responses.","volume":"147","author":"Martires","year":"2011","journal-title":"Arch Dermatol"},{"issue":"5","key":"2019111807103569200_B27","first-page":"883","article-title":"Irradiation of the skin and systemic graft-versus-host disease synergize to produce cutaneous lesions.","volume":"144","author":"Desbarats","year":"1994","journal-title":"Am J Pathol"},{"issue":"3","key":"2019111807103569200_B28","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.jaad.2007.10.647","article-title":"CXCR3 <-> ligand-mediated skin inflammation in cutaneous lichenoid graft-versus-host disease.","volume":"58","author":"Wenzel","year":"2008","journal-title":"J Am Acad Dermatol"},{"issue":"12","key":"2019111807103569200_B29","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1038\/nri2873","article-title":"Sterile inflammation: sensing and reacting to damage.","volume":"10","author":"Chen","year":"2010","journal-title":"Nat Rev Immunol"},{"issue":"2","key":"2019111807103569200_B30","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1002\/art.27224","article-title":"Systemic sclerosis and lupus: points in an interferon-mediated continuum.","volume":"62","author":"Assassi","year":"2010","journal-title":"Arthritis Rheum"},{"issue":"1","key":"2019111807103569200_B31","doi-asserted-by":"crossref","first-page":"71","DOI":"10.3109\/09553002.2010.518208","article-title":"Different radiosensitivity of CD4(+)CD25(+) regulatory T cells and effector T cells to low dose gamma irradiation in vitro.","volume":"87","author":"Cao","year":"2011","journal-title":"Int J Radiat Biol"},{"issue":"2","key":"2019111807103569200_B32","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1038\/sj.jid.5700517","article-title":"Cutaneous gene expression by DNA microarray in murine sclerodermatous graft-versus-host disease, a model for human scleroderma.","volume":"127","author":"Zhou","year":"2007","journal-title":"J Invest Dermatol"},{"issue":"4","key":"2019111807103569200_B33","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1046\/j.1523-1747.2003.12517.x","article-title":"Latency-associated peptide prevents skin fibrosis in murine sclerodermatous graft-versus-host disease, a model for human scleroderma.","volume":"121","author":"Zhang","year":"2003","journal-title":"J Invest Dermatol"},{"issue":"10","key":"2019111807103569200_B34","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1002\/anr.1780321011","article-title":"Activation of the complement system in systemic sclerosis. Relationship to clinical severity.","volume":"32","author":"Senaldi","year":"1989","journal-title":"Arthritis Rheum"},{"issue":"2","key":"2019111807103569200_B35","first-page":"323","article-title":"Association of circulating immune complexes containing bovine proteins and graft-versus-host disease.","volume":"64","author":"Cunningham-Rundles","year":"1986","journal-title":"Clin Exp Immunol"},{"issue":"3","key":"2019111807103569200_B36","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/sj.bmt.1705725","article-title":"Treatment of refractory chronic GVHD with rituximab: a GITMO study.","volume":"40","author":"Zaja","year":"2007","journal-title":"Bone Marrow Transplant"},{"issue":"16","key":"2019111807103569200_B37","doi-asserted-by":"crossref","first-page":"3865","DOI":"10.1182\/blood-2008-09-177840","article-title":"Altered B-cell homeostasis and excess BAFF in human chronic graft-versus-host disease.","volume":"113","author":"Sarantopoulos","year":"2009","journal-title":"Blood"},{"issue":"6","key":"2019111807103569200_B38","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1189\/jlb.1007676","article-title":"TGF-beta1 and IFN-gamma stimulate mouse macrophages to express BAFF via different signaling pathways.","volume":"83","author":"Kim","year":"2008","journal-title":"J Leukoc Biol"},{"issue":"8","key":"2019111807103569200_B39","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1038\/ng1599","article-title":"Complement factor 5 is a quantitative trait gene that modifies liver fibrogenesis in mice and humans.","volume":"37","author":"Hillebrandt","year":"2005","journal-title":"Nat Genet"},{"issue":"1","key":"2019111807103569200_B40","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1158\/1078-0432.CCR-10-1198","article-title":"Interleukin-6 modulates graft-versus-host responses after experimental allogeneic bone marrow transplantation.","volume":"17","author":"Tawara","year":"2011","journal-title":"Clin Cancer Res"},{"issue":"5","key":"2019111807103569200_B41","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1056\/NEJM197802022980502","article-title":"Circulating immune complexes and complement activation in primary biliary cirrhosis.","volume":"298","author":"Wands","year":"1978","journal-title":"N Engl J Med"},{"issue":"4","key":"2019111807103569200_B42","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1182\/blood.V74.4.1428.1428","article-title":"Predictors of death from chronic graft-versus-host disease after bone marrow transplantation.","volume":"74","author":"Wingard","year":"1989","journal-title":"Blood"},{"issue":"3","key":"2019111807103569200_B43","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.thromres.2005.03.003","article-title":"Increase in platelet non-integrin type I collagen receptor in patients with systemic sclerosis.","volume":"117","author":"Chiang","year":"2006","journal-title":"Thromb Res"},{"issue":"6","key":"2019111807103569200_B44","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1097\/BOR.0b013e3282eeb3a4","article-title":"Platelet contributions to the pathogenesis of systemic sclerosis.","volume":"19","author":"Postlethwaite","year":"2007","journal-title":"Curr Opin Rheumatol"},{"issue":"2","key":"2019111807103569200_B45","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/0002-9343(80)90380-0","article-title":"Chronic graft-versus-host syndrome in man: a long-term clinicopathologic study of 20 Seattle patients.","volume":"69","author":"Shulman","year":"1980","journal-title":"Am J Med"},{"issue":"1","key":"2019111807103569200_B46","doi-asserted-by":"crossref","first-page":"133","DOI":"10.2217\/bmm.09.79","article-title":"Biomarkers in systemic sclerosis.","volume":"4","author":"Castro","year":"2010","journal-title":"Biomark Med"},{"issue":"2","key":"2019111807103569200_B47","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1097\/00007890-198808000-00010","article-title":"Autoimmunity after allogeneic bone marrow transplantation. A study of 53 long-term-surviving patients.","volume":"46","author":"Rouquette-Gally","year":"1988","journal-title":"Transplantation"},{"issue":"4","key":"2019111807103569200_B48","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1038\/bmt.2009.238","article-title":"Determinants of functional performance in long-term survivors of allogeneic hematopoietic stem cell transplantation with chronic graft-versus-host disease (cGVHD).","volume":"45","author":"Mitchell","year":"2010","journal-title":"Bone Marrow Transplant"},{"issue":"5","key":"2019111807103569200_B49","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1002\/art.1780200506","article-title":"Pulmonary function in scleroderma.","volume":"20","author":"Guttadauria","year":"1977","journal-title":"Arthritis Rheum"},{"issue":"4","key":"2019111807103569200_B50","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1590\/S1806-37132010000400011","article-title":"Predicting reduced TLC in patients with low FVC and a normal or elevated FEV1\/FVC ratio.","volume":"36","author":"D'Aquino","year":"2010","journal-title":"J Bras Pneumol"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/118\/15\/4250\/1342785\/zh804111004250.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/118\/15\/4250\/1342785\/zh804111004250.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,18]],"date-time":"2019-11-18T07:13:35Z","timestamp":1574061215000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/118\/15\/4250\/29060\/Sclerotictype-chronic-GVHD-of-the-skin-clinical"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,10,13]]},"references-count":50,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2011,10,13]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2011-04-350249","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,10,13]]}}}